• Juan G Ripoll, Rayssa Becerra Orjuela, Jamel Ortoleva, Christoph S Nabzdyk, Serena Dasani, Subasish Bhowmik, Aditi Balakrishna, Stephan Hain, Marvin G Chang, Edward A Bittner, and Harish Ramakrishna.
• Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
• J. Cardiothorac. Vasc. Anesth. 2024 Dec 1; 38 (12): 322432333224-3233.

AbstractHeart failure (HF) remains a public health concern affecting millions of individuals worldwide. Despite recent advances in device-related therapies, the prognosis for patients with chronic HF remains poor with significant long-term risk of morbidity and mortality. Left ventricular assist devices (LVADs) have transformed the landscape of advanced HF management, offering circulatory support as destination therapy or as a bridge for heart transplantation. Among the latest generation of LVADs, the HeartMate 3 has gained popularity due to improved clinical outcomes and lower risk of serious adverse events when compared with previous similar devices. The ELEVATE (Evaluating the HeartMate 3 with Full MagLev Technology in a Post-Market Approval Setting) Registry and the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) trial represent landmark investigations into the performance and comparative effectiveness of the HeartMate 3 LVAD. This review provides a comprehensive synthesis of the safety and efficacy of the 2-year and 5-year HeartMate LVAD outcomes, highlighting key findings, methodological considerations, implications for clinical practice, and future directions.Copyright © 2024 Elsevier Inc. All rights reserved.

15 keywords...

hide…